Docetaxel, a taxane type anticancer drug, developed by Sanofi-Aventis and marketed under the brand name of Taxotere, lost its molecule patent protections in US and major European jurisdictions last month.

Like most Hatch-Waxman attorneys, we couldn't help but notice the mysterious allure of the new inter partes review (IPR) procedure.

Valsartan, an angiotensin II receptor antagonist, developed by Novartis and marketed as its flagship-product, is sold under the brand name Diovan.

Donepezil (Aricept®), an anti-dementia/anti-Alzheimer's treatment developed by Eisai and co-marketed by Pfizer, will lose key patent protection in some major territories in the near future. Currently, Aricept® is the world's best selling anti-Alzheimer's drug and generated sales of 303 billion Japanese Yen for Eisai and US$432 million for Pfizer in 2009. Based on the information contained in GenericsWeb's Donepezil Pipeline Selector report, this month's Drug In Focus will analyse the patent land

The Anastrozole General Information indicates that Arimidex is available as 1 mg film coated tablets and generally carries three indications relating to the treatment of breast cancer.